(GRTX) – Press Releases
-
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
-
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
-
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
-
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
-
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
-
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
-
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
-
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
-
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
-
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
-
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Galera Expands Commercial Leadership Team
-
Galera Expands Commercial Leadership Team
-
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
-
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
-
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
-
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
-
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
-
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
-
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
-
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
-
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
-
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
-
Galera to Present at Piper Sandler Annual Healthcare Conference
-
Galera to Present at Piper Sandler Annual Healthcare Conference
-
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
-
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
-
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
-
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
-
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
-
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
-
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
-
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
-
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
-
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
-
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
-
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
-
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
-
Galera to Present at Jefferies Healthcare Conference
-
Galera to Present at Jefferies Healthcare Conference
-
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
-
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
-
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
-
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
-
Galera Announces Plan to Submit Avasopasem NDA by Year End
-
Galera Announces Plan to Submit Avasopasem NDA by Year End
-
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
Back to GRTX Stock Lookup
